Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acute Myelogenous Leukemia: early-phase trial registry
7 of 39 indexed Acute Myelogenous Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #382 of 28,707 conditions by registered trial count.
39 US clinical trials · 7 currently recruiting · #382 of 28,707 conditions by registered trial count
Acute Myelogenous Leukemia: 39 US clinical trials tracked, 7 recruiting.
Acute Myelogenous Leukemia is the subject of 39 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 31 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition acute-myelogenous-leukemia
OPEN 7 | RECR 18% | LATE 2 | EARLY 31 | RANK #382 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Diabetes Mellitus, Type 2 (18% recruiting · 351 trials)
Acute Myelogenous Leukemia lists 7 open slots (18% of 39 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acute Myelogenous Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acute Myelogenous Leukemia is recruiting below its size-band peers.
7 of 39 indexed trials (17.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Acute Myelogenous Leukemia trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 4 of 39 trials (10.3%). 29 distinct sponsors appear on at least one study for this condition label.
-
Most Acute Myelogenous Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 37 among the 39 trials that report a genuine target (sentinel values excluded). 29 of those (74.4%) plan for fewer than 100 participants.
-
Acute Myelogenous Leukemia research is mostly interventional.
35 interventional and 4 observational studies make up this index (89.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
39 total, page 1 of 1
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Wake Forest University Health Sciences
NCT01890486
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Beijing InnoCare Pharma Tech Co.
NCT06656494
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT05805605
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
Case Comprehensive Cancer Center
NCT06904482
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Children's Hospital Medical Center, Cincinnati
NCT06131801
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
Carevive Systems
NCT05974150
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
Leland Metheny
NCT06680661
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
NCT04904588
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Actinium Pharmaceuticals
NCT02665065
DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission
Beth Israel Deaconess Medical Center
NCT03059485
Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia
Center for International Blood and Marrow Transplant Research
NCT03971799
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Bellicum Pharmaceuticals
NCT01744223
Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients
Beth Israel Deaconess Medical Center
NCT03679650
Selecting a Favorable KIR Donor in Unrelated HCT for AML
Masonic Cancer Center, University of Minnesota
NCT01288222
A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)
Genzyme, a Sanofi Company
NCT00317642
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
National Heart, Lung, and Blood Institute (NHLBI)
NCT00003838
Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
M.D. Anderson Cancer Center
NCT00414310
Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy
Notable Labs
NCT04014764
A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)
Genzyme, a Sanofi Company
NCT00373529
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
Bristol-Myers Squibb
NCT01120457
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT00968071
A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia
Mirati Therapeutics
NCT00324220
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Washington University School of Medicine
NCT03755414
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
AbbVie (prior sponsor, Abbott)
NCT01110473
A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)
Weill Medical College of Cornell University
NCT00875693
Epigenetic Reprogramming in Relapse/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
NCT03263936
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT
University of California, San Francisco
NCT00516152
Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
NCT00569010
Lenalidomide Plus Chemotherapy for AML
Massachusetts General Hospital
NCT01681537
Phase II 5-Azacytidine Plus VPA Plus ATRA
M.D. Anderson Cancer Center
NCT00326170
Reduced Intensity Double Umbilical Cord Blood Transplantation
Massachusetts General Hospital
NCT01408563
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
Dana-Farber Cancer Institute
NCT00144677
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
Sanofi
NCT00981240
Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia
Dana-Farber Cancer Institute
NCT00136422
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
Dartmouth-Hitchcock Medical Center
NCT00789256
SCT Plus Immune Therapy in Average Risk AML/MDS
New York Medical College
NCT02117297
Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS
New York Medical College
NCT02221310
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Northside Hospital
NCT02581007
A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)
Asterias Biotherapeutics
NCT00510133
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 17 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Acute Myelogenous Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acute Myelogenous Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acute Myelogenous Leukemia page
39 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Acute Myelogenous Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Acute Myelogenous Leukemia trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Myelogenous Leukemia condition card totals 39 registered trials; most-linked intervention Fludarabine; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.